Pub. Date : 2022 Apr
PMID : 35066105
1 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
1 | RESULTS: Among the 45 patients included in MATCH-R who progressed on osimertinib, nine developed a second targetable alteration (n = 2 FGFR3-TACC3, n = 1 KIF5B-RET, n = 1 STRN-ALK fusions; n = 2 BRAFV600E, n = 1 KRASG12V, n = 1 KRASG12R, n = 1 KRASG12D mutations). | osimertinib | ret proto-oncogene | Homo sapiens |